title: Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis.
abstract: A number of studies investigated the impact of matrix metalloproteinase 2 (MMP2) expression on the survival of patients with osteosarcoma, but no consistent results were reported. To derive a more precise estimate of the prognostic role of MMP2 expression in patients with osteosarcoma, we systematically reviewed the published studies and carried out a meta-analysis. Cohort studies assessing the prognostic role of MMP2 expression in patients with osteosarcoma were included. Pooled risk ratio (RR) with 95% confidence intervals (95%CI) was used to assess the prognostic role of MMP2 expression. Five cohort studies were eligible in the meta-analysis. Overall, high MMP2 expression was associated with increased risk of mortality in patients with osteosarcoma during the follow-up (fixed effects RR = 2.14, 95%CI 1.66-2.75, P < 0.001). Sensitivity analysis suggested that the pooled RR was stable and omitting a single study did not change the significance of the pooled RR. There was some possibility of publication bias risk in the meta-analysis. In conclusion, the meta-analysis suggests that osteosarcoma patients with high MMP2 expression have poorer prognosis compared with those with low MMP2 expression.
authors.affiliation: Department of Orthopedics Surgery, Xinyu People's Hospital, Xinyu, 338025, Jiangxi province, China.
authors.forename: Xiaoyang
authors.initials: X
authors.lastname: Wen
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.forename: Kailong
authors.initials: K
authors.lastname: Yu
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
mesh_terms: D001859:Bone Neoplasms / Q000235:genetics* / Q000401:mortality*; D015870:Gene Expression; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000235:genetics*; D016017:Odds Ratio; D012516:Osteosarcoma / Q000235:genetics* / Q000401:mortality*; D011379:Prognosis; D017594:Publication Bias
chemical_list: D020778:Matrix Metalloproteinase 2
references.citation: Lancet Oncol. 2005 Feb;6(2):85-92
references.pmid: 15683817
references.citation: Cell. 2010 Apr 2;141(1):52-67
references.pmid: 20371345
references.citation: Cancer Metastasis Rev. 2009 Jun;28(1-2):247-63
references.pmid: 19214708
references.citation: Bull Exp Biol Med. 2010 Aug;149(2):233-5
references.pmid: 21113498
references.citation: Ortop Traumatol Rehabil. 2011 Nov-Dec;13(6):537-45
references.pmid: 22248458
references.citation: Lancet Oncol. 2010 Feb;11(2):184-92
references.pmid: 20152770
references.citation: J Clin Oncol. 2000 Mar;18(5):1135-49
references.pmid: 10694567
references.citation: J Comp Pathol. 2012 Feb-Apr;146(2-3):132-42
references.pmid: 22297074
references.citation: J Clin Epidemiol. 2008 Jul;61(7):634-45
references.pmid: 18538260
references.citation: Oncogene. 2010 Aug 12;29(32):4504-16
references.pmid: 20543858
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Ann Oncol. 2010 Oct;21 Suppl 7:vii320-5
references.pmid: 20943636
references.citation: Int J Oncol. 2006 Jan;28(1):33-42
references.pmid: 16327977
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Lung Cancer. 2002 Mar;35(3):249-55
references.pmid: 11844598
references.citation: Nat Rev Cancer. 2002 Mar;2(3):161-74
references.pmid: 11990853
references.citation: Lancet Oncol. 2005 Sep;6(9):678-86
references.pmid: 16129368
references.citation: Acta Biochim Biophys Sin (Shanghai). 2011 Nov;43(11):840-8
references.pmid: 21968416
references.citation: Curr Opin Cell Biol. 2009 Oct;21(5):645-53
references.pmid: 19616423